Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

ABSTRACT:

SUBMITTER: Waldschmidt JM 

PROVIDER: S-EPMC6165805 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature